CooperCompanies (NASDAQ: COO) has announced its financial results for the fiscal third quarter ending July 31, 2024. The company reported a revenue increase of 8% year-over-year to $1,002.8 million.
San Ramon, California-based The Cooper Companies, Inc. (COO) is a global medical device company that develops and ...
The Cooper Companies, Inc.’s COO growth is fueled by CooperVision’s premium lens migration and MiSight’s myopia-management leadership, supported by CooperSurgical’s women’s health and fertility ...
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter can be downloaded here.
COO's premium lens, myopia control and fertility momentum support growth, but Asia-Pacific weakness and margin pressure keep the outlook measured.